Scientists probe skin to unlock eczema Drug's secrets
NCT ID NCT05378698
Summary
This study aimed to understand how the drug tralokinumab works in the skin of people with moderate to severe eczema (atopic dermatitis). Researchers took skin and blood samples from 24 patients to measure the drug's levels and see how it changed the body's immune response. The goal was to learn more about the drug's mechanism to help doctors better predict which patients it will help most.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich
Zurich, Canton of Zurich, 8091, Switzerland
Conditions
Explore the condition pages connected to this study.